Simultaneous isolation of CD8+ and CD4+ T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation

Journal of Immunotherapy

Volumn 34, Issue 3, 2011, Pages 307-319

  Zandvliet, Maarten L ^a   Van Liempt, Ellis ^a   Jedema, Inge ^a   Kruithof, Simone ^a   Kester, Michel G D ^a   Guchelaar, Henk Jan ^a   Falkenburg, J H Frederik ^a   Meij, Pauline ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

adoptive immunotherapy; allogeneic stem cell transplantation; CD137 expression; interferon g production; virus specific T cells

Indexed keywords

BMLF1 PROTEIN; BRLF1 PROTEIN; CD137 ANTIGEN; CYTOMEGALOVIRUS ANTIGEN PP65; EPITOPE; EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN 3A; EPSTEIN BARR VIRUS ANTIGEN 3C; GAMMA INTERFERON; IE1; IMMEDIATE EARLY PROTEIN BZLF1; INTERLEUKIN 2; MATRIX PROTEIN; PP50 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; AMINO ACID SEQUENCE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; DEGRANULATION; ENRICHMENT CULTURE; EPSTEIN BARR VIRUS; HUMAN; HUMAN ADENOVIRUS; HUMAN CELL; INFLUENZA VIRUS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MEMORY CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL CLEARANCE; VIRUS NUCLEOCAPSID;

ADAPTIVE IMMUNITY; ADENOVIRUSES, HUMAN; ADOPTIVE TRANSFER; AMINO ACID SEQUENCE; ANTIGENS, CD137; ANTIGENS, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC MEMORY; IMMUNOMAGNETIC SEPARATION; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; OPPORTUNISTIC INFECTIONS; ORTHOMYXOVIRIDAE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953063320     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318213cb90     Document Type: Article

References (41)

1. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4:725-738. (Pubitemid 39574344)
2. Walls T, Shankar AG, Shingadia D. Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients. Lancet Infect Dis. 2003;3:79-86. (Pubitemid 36164203)
3. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomega-lovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101:407-414. (Pubitemid 36077556)
4. Baldanti F, Lurain N, Gerna G. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Hum Immunol. 2004;65:403-409. (Pubitemid 38686763)
5. Annels NE, Kalpoe JS, Bredius RG, et al. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis. 2006; 42:1743-1748. (Pubitemid 43839440)
6. Chakrabarti S, Milligan DW, Pillay D, et al. Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmye-loablative allogeneic stem cell transplantation. Blood. 2003;102: 839-842. (Pubitemid 36917773)
7. Heemskerk B, Lankester AC, van Vreeswijk T, et al. Immune reconstitution and clearance of human adenovirus viremia in pediatric stem-cell recipients. J Infect Dis. 2005;191:520-530. (Pubitemid 40216667)
8. Lilleri D, Gerna G, Fornara C, et al. Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants. Blood. 2006;108: 1406-1412. (Pubitemid 44232045)
9. Meij P, van Esser JW, Niesters HG, et al. Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood. 2003; 101:4290-4297. (Pubitemid 36857791)
10. Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomega-lovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 2002;99:3916-3922. (Pubitemid 35332029)
11. Feuchtinger T, Matthes-Martin S, Richard C, et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol. 2006;134:64-76. (Pubitemid 43830030)
12. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lympho-proliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110:1123-1131. (Pubitemid 47281407)
13. Leen AM, Myers GD, Sili U, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006;12:1160-1166. (Pubitemid 44527351)
14. Peggs KS, Verfuerth S, Pizzey A, et al. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet. 2003;362:1375-1377. (Pubitemid 37338339)
15. Cobbold M, Khan N, Pourgheysari B, et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med. 2005;202:379-386. (Pubitemid 41126955)
16. Elkington R, Walker S, Crough T, et al. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol. 2003;77:5226-5240. (Pubitemid 36460937)
17. Hislop AD, Annels NE, Gudgeon NH, et al. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med. 2002;195:893-905. (Pubitemid 34286760)
18. Leen AM, Christin A, Khalil M, et al. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 2008;82:546-554. (Pubitemid 350309169)
19. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202:673-685. (Pubitemid 41248418)
20. Altman JD, Moss PA, Goulder PJ, et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 1996;274:94-96. (Pubitemid 26332731)
21. Kiecker F, Streitz M, Ay B, et al. Analysis of antigen-specific T-cell responses with synthetic peptides-what kind of peptide for which purpose?. Hum Immunol. 2004;65:523-536. (Pubitemid 38686777)
22. Trivedi D, Williams RY, O'Reilly RJ, et al. Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood. 2005;105:2793-2801. (Pubitemid 40446272)
23. Leen A, Meij P, Redchenko I, et al. Differential immunogeni-city of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol. 2001;75:8649-8659. (Pubitemid 32768969)
24. Meij P, Leen A, Rickinson AB, et al. Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int J Cancer. 2002;99:93-99. (Pubitemid 34273204)
25. Scherrenburg J, Piriou ER, Nanlohy NM, et al. Detailed analysis of Epstein-Barr virus-specific CD4+ and CD8+ T cell responses during infectious mononucleosis. Clin Exp Immunol. 2008;153:231-239. (Pubitemid 351989168)
26. Zandvliet ML, Liempt EV, Jedema I, et al. Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy. Cytotherapy. 2010;12: 933-944.
27. Rauser G, Einsele H, Sinzger C, et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood. 2004;103:3565-3572. (Pubitemid 38525695)
28. Fujita Y, Leen AM, Sun J, et al. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 2008;31:665-674.
29. + adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection. Haematologica. 2010;95:1943-1951.
30. Mackinnon S, Thomson K, Verfuerth S, et al. Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis. 2008;40:63-67. (Pubitemid 350192302)
31. Meij P, Zandvliet ML, Van der Heiden PLJ, et al. Generation and administration of CMV pp65-specific donor T-cell lines for treatment of CMV reactivation after allogeneic stem cell transplantation. Annu Meet EBMT. 2007;O-292.
32. Zandvliet ML, Falkenburg JH, Jedema I, et al. Detailed analysis of IFNg response upon activation permits efficient isolation of cytomegalovirus-specific CD8+ T cells for adoptive immunotherapy. J Immunother. 2009;32:513-523.
33. Wolfl M, Kuball J, Ho WY, et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood. 2007;110:201-210. (Pubitemid 47026836)
34. Wehler TC, Karg M, Distler E, et al. Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression. J Immunol Methods. 2008;339:23-37.
35. Watanabe K, Suzuki S, Kamei M, et al. CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy. Int J Hematol. 2008; 88:311-320.
36. Wehler TC, Nonn M, Brandt B, et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines. Blood. 2007;109:365-373. (Pubitemid 46053079)
37. Faber LM, Luxemburg-Heijs SA, Willemze R, et al. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med. 1992;176:1283-1289.
38. Jedema I, van der Werff NM, Barge RM, et al. New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood. 2004;103:2677-2682. (Pubitemid 38393024)
39. van Lier RA, ten Berge IJ, Gamadia LE. Human CD8(+) T-cell differentiation in response to viruses. Nat Rev Immunol. 2003;3:931-939.
40. Karlsson H, Brewin J, Kinnon C, et al. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens. J Immunother. 2007;30: 544-556. (Pubitemid 46988088)
41. Leen AM, Christin A, Myers GD, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploiden-tical and matched unrelated stem cell transplant. Blood. 2009; 114:4283-4292.